Status:
UNKNOWN
Study of Comparison the Treatment Effect Between Gastric Bypass and Exenatide in Type 2 Diabetes
Lead Sponsor:
Wu Qinan
Conditions:
Type 2 Diabetes
Eligibility:
All Genders
18-60 years
Phase:
PHASE4
Brief Summary
Objectives: To investigate the treatment effect between Gastric Bypass and Exenatide in Type 2 Diabetes in our hospital, in order to investigate the possible mechanism of Gastric Bypass and Exenatide.
Detailed Description
Methods: 60 Type 2 diabetes in our hospital will divide into 3 groups: group A (20 patients who give basal treatment), group B (20 patients who give basal and Exenatide treatment, group C（20 patients...
Eligibility Criteria
Inclusion
- BMI ≥ 35kg/m2, With Type 2 Diabetes;
- BMI32-34.9kg/m2, With Type 2 Diabetes, Insulin Therapy in Combination With Oral Administration of Drugs for 6 Months and HbA1c ≥ 7%;
- Between the Ages of 18-60 Years;
- Course of Type 2 Diabetes ≤ 5 Years;
- ICA, IAA, GAD Are Negative , C-peptide Level is Not Less Than 0.3mg / L;
Exclusion
- non-diabetic patients , type 1 diabetes (serum insulin antibodies (ICA) or glutamic acid decarboxylase antibodies (GADA)-positive autoimmune diabetes), special type of diabetes, gestational diabetes;
- patients who had liver or renal failure
- severe infections in patients and patients who had cerebrovascular disease
- patients who had heart failure
- fasting serum insulin or 2-hour postprandial serum insulin were lower than normal (\<20mmol / L)
- course of diabetes\> 5 years or age\> 60 years or age \<18 years
Key Trial Info
Start Date :
February 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 1 2016
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT01435980
Start Date
February 1 2008
End Date
February 1 2016
Last Update
March 27 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Endocrine Department, the south west Hospital of the Third Military Medical University
Chongqing, Chongqing Municipality, China, 400038